Allied Market Research
Loading...
0
New
New
2021
Cardiac Biomarkers Testing Market

Cardiac Biomarkers Testing Market by Biomarkers Type (Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP and NT-proBNP), Ischemia Modified Albumins, and Other Biomarkers Type), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), and Location of Testing (Point-of-care Testing and Laboratory Testing): Global Opportunity Analysis and Industry Forecast, 2021-2030

A04921
Pages: 235
Jul 2021 | 6280 Views
   
Author(s) : Kishor Sherkar, Vikita Thakur , Onkar Sumant
Tables: 109
Charts: 53
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cardiac Biomarkers Testing Market

Request Now !

The global cardiac biomarkers testing market was valued at $9,766.93 million in 2020, and is projected to reach $28,098.07 million by 2030, registering a CAGR of 10.9% from 2021 to 2030. Cardiac biomarkers are protein molecules that are released into the blood after heart damage or heart-stress. These biomarkers act as a potential tool to detect various cardiovascular diseases (CVD) including cardiac ischemia, myocardial infarction, congestive heart failure, and acute coronary syndrome (ACS). Cardiac biomarker tests allow the doctor to determine the risk of a patient associated with such diseases.

The impact of COVID-19 pandemic is expected to remain positive for the cardiac biomarker testing market. Owing to increase in medical condition such as diabetes heart diseases among others which are more vulnerable to COVID-19. Furthermore, it was estimated that Troponin levels were significantly higher in COVID-19 patients who died or were critically ill due to which cardiac injury biomarkers were elevated in most of the complicated cases of COVID-19.

Cardiac-Biomarkers-Testing-Market-2021-2030

Get more information on this report : Request Sample Pages

These tests are performed after the patient suffers chest pain. The common cardiac biomarkers that are tested for CVD include troponin, creatine kinase-muscle/brain (CK-MB), B-type natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), and others. Cardiac biomarkers that are widely used as an integrated diagnostic approach for cardiovascular diseases (CVDs) include myocardial muscle creatine kinase (CK-MB), troponin I and T, myoglobin, brain natriuretic peptide (BNPs), ischemia modified albumin (IMA), and others. 

The impact of COVID-19 pandemic is expected to remain positive for the cardiac biomarkers testing industry. Owing to increase in the number of COVID-19 patient with preexisting medical condition like cardiovascular diseases and among others. As these patients with existing medical conditions like cardiovascular disease suffering from COVID-19 are more heart attack. Furthermore, it was estimated that troponin levels were significantly higher in COVID-19 patients who died or were critically ill. This has led to increase in the demand of cardiac biomarker testing for the patients suffering from COVID-19. Thus, considering all these factors, the global cardiac biomarkers testing market exhibits positive growth during this pandemic and is expected to gain traction in the upcoming years.

Increase in geriatric population and rise in number of patients suffering from heart attacks & chest pain due to changes in lifestyles are expected to drive the market in the coming years. Furthermore, rise in funding from public and private organizations for research on cardiac biomarkers is expected to boost the market growth in the upcoming years.

However, factors such as limited specificity in some cases and side effects associated with cardiac biomarkers such as skeletal muscle injury are likely to hinder the cardiac biomarkers testing market growth in the upcoming years.

The cardiac biomarkers testing market is segmented on the basis of biomarker type, application, and location of testing. By cardiac biomarker type, the market is divided into creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia modified albumins, and other biomarkers type. By application, the market is classified into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. By location of testing, the market is bifurcated into point of care testing and laboratory testing. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Cardiac biomarker type segment review

By cardiac biomarker type segment, the troponin segment held the largest share in 2020 and is anticipated to maintain its dominance during the forecast period. This large share is due to increase in the prevalence of acute coronary syndrome and myocardium infarction, rise in the number of congestive heart failure cases across the globe are the key factors to drive the market growth. The creatine kinase is estimated to grow at the highest CAGR 13.0% during the forecast period.

Cardiac Biomarkers Testing Market
By Biomarker Types

Your browser does not support the canvas element.

Troponin segment dominated the market in 2020 and will continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Application segment review

By application, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. The myocardial infarction accounted for the larger share in 2020, whereas, congestive Heart Failure segment is the faster growing segment with a CAGR of 12.2% owing to increase in cardiovascular disease and increased demand for biomarker tests for early detection of heart failure are key factors anticipated to boost the growth of the global cardiac biomarkers testing market in future.

Cardiac Biomarkers Testing Market
By Application

Your browser does not support the canvas element.

Myocardial infarction segment held the dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Location of testing segment review

On the basis of location of testing, the laboratory testing segment held the largest share in 2020 and is anticipated to maintain its dominance during the forecast period, owing to the reform in healthcare infrastructure, increase in healthcare spending, rise in disposable incomes, and government initiatives for preventing heart attack are expected to drive the cardiac biomarkers testing market in the Asia-Pacific region. Thus, the increase in cardiovascular diseases (CVDs) around the globe, has augmented the demand for cardiac biomarkers testing for lowering the burden of heart attack and other CVDs.

Cardiac Biomarkers Testing Market
By Location of Testing

Your browser does not support the canvas element.

Laboratory Testing segement held a dominant position in 2020 and continue to maintain lead in the forecast year

Get more information on this report : Request Sample Pages

Region segment review

By region, North America accounted for the largest share in 2020, and is anticipated to maintain its dominance from 2020 to 2030, due to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR of 12.5% during the forecast period, as Governments of Asian countries are investing in the development of healthcare infrastructure.

Cardiac Biomarkers Testing Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 12.50% during 2020-2028.

Get more information on this report : Request Sample Pages

Some of the key players operating in the global cardiac biomarkers testing market include Abbott Laboratories, Becton, Dickinson and Company, bioMerieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Siemens AG, Thermo Fisher Scientific, Inc., and Tosoh Corporation. 

Key Benefits For Stakeholders

  • This report entails a detailed quantitative analysis along with the current global cardiac biomarkers testing market trends from 2020 to 2030 to identify the prevailing opportunities along with the strategic assessment.
  • The cardiac biomarkers testing market forecast is studied from 2020 to 2030.
  • The market size and estimations are based on a comprehensive analysis of key developments in the cardiac biomarkers testing industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the cardiac biomarkers testing market.


Key Market Segments

  • BY BIOMARKERS TYPE
    • Creatine kinase (CK-MB)
    • Troponins
    • Myoglobin
    • Natriuretic peptides (BNP and NT-proBNP)
    • Ischemia modified albumin (IMA)
    • Other biomarkers type
  • By Application
    • Myocardial Infarction
    • Congestive Heart Failure
    • Acute coronary syndrome (ACS)
    • Atherosclerosis
    • Other applications
  • By Location Of Testing
    • Point of Care Testing
    • Laboratory Testing
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Uk
      • France
      • Germany
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Australia
      • Japan
      • Rest of Asia-Pacific
    • LAMEA
      • Latin America
      • Middle East
      • Africa


Key Market Players

  • ABBOTT LABORATORIES
  • BECTON, DICKINSON AND COMPANY
  • BIOMERIEUX, INC.
  • BIO-RAD LABORATORIES, INC.
  • DANAHER CORPORATION
  • F. HOFFMANN-LA ROCHE LTD.
  • PERKINELMER INC.
  • SIEMENS AG
  • THERMO FISHER SCIENTIFIC, INC.
  • TOSOH CORPORATION
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope

3.1.1.Biomarker diagnosis vs. conventional diagnosis

3.2.Assessment of key advantages and buying criteria for diagnostic biomarkers

3.2.1.Early diagnosis
3.2.2.Tissue specific diagnosis
3.2.3.Reduce clinical trials
3.2.4.Consistent output

3.3.Key trends impacting the cardiac biomarker testing market

3.3.1.Development of highly sensitive biomarkers for risk stratification
3.3.2.Technological advancements in the cardiac biomarker testing: Serum based biomarkers
3.3.3.Increasing demand for Point-of-care cardiac diagnostics

3.4.Key forces shaping cardiac biomarkers testing market

3.4.1.Top investment pockets

3.5.Top player positioning, 2020
3.6.Value chain analysis
3.7.Government regulations
3.8.Reimbursement issues
3.9.Market dynamics

3.9.1.Drivers

3.9.1.1.Increase in prevalence of cardiovascular diseases
3.9.1.2.Non-invasive Biomarkers66
3.9.1.3.Increase in point-of-care (POC) testing

3.9.2.Restraints

3.9.2.1.Stringent Government Regulation
3.9.2.2.Complex process

3.9.3.Opportunities

3.9.3.1.Personalized medicine
3.9.3.2.Point-of-care (POCT) testing using cardiac biomarker testing

3.9.4.Impact analysis

3.10.Analysis of COVID-19-Impact on the Market

CHAPTER 4:CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Creatine kinase (CK-MB)

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Troponins

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Myoglobin

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Natriuretic peptides (BNP and NT-proBNP)

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Ischemia modified albumin (IMA)

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

4.7.Other biomarkers type

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country

CHAPTER 5:CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Myocardial Infarction

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Congestive heart failure

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Acute coronary syndrome (ACS)

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Atherosclerosis

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Other applications

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

CHAPTER 6:CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING

6.1.Overview

6.1.1.Market size and forecast

6.2.Point-of-care testing

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Laboratory testing

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

CHAPTER 7:CARDIAC BIOMARKERS TESTING MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. Cardiac biomarkers testing market, by Biomarkers Type
7.2.2.1.2.U.S. Cardiac biomarkers testing market, by application
7.2.2.1.3.U.S. Cardiac biomarkers testing market, by location of testing

7.2.2.2.Canada

7.2.2.2.1.Canada Cardiac biomarkers testing market, by Biomarkers Type
7.2.2.2.2.Canada Cardiac biomarkers testing market, by application
7.2.2.2.3.Canada Cardiac biomarkers testing market, by location of testing

7.2.2.3.Mexico

7.2.2.3.1.Mexico Cardiac biomarkers testing market, by Biomarkers Type
7.2.2.3.2.Mexico Cardiac biomarkers testing market, by application
7.2.2.3.3.Mexico Cardiac biomarkers testing market, by location of testing

7.2.3.North America market size and forecast, by Biomarkers Type
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by location of testing

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.UK

7.3.2.1.1.UK Cardiac biomarkers testing market, by Biomarkers Type
7.3.2.1.2.UK Cardiac biomarkers testing market, by application
7.3.2.1.3.UK Cardiac biomarkers testing market, by location of testing

7.3.2.2.France

7.3.2.2.1.France Cardiac biomarkers testing market, by Biomarkers Type
7.3.2.2.2.France Cardiac biomarkers testing market, by application
7.3.2.2.3.France Cardiac biomarkers testing market, by location of testing

7.3.2.3.Germany

7.3.2.3.1.Germany Cardiac biomarkers testing market, by Biomarkers Type
7.3.2.3.2.Germany Cardiac biomarkers testing market, by application
7.3.2.3.3.Germany Cardiac biomarkers testing market, by location of testing

7.3.2.4.Rest of Europe

7.3.2.4.1.Rest of Europe Cardiac biomarkers testing market, by Biomarkers Type
7.3.2.4.2.Rest of Europe Cardiac biomarkers testing market, by application
7.3.2.4.3.Rest of Europe Cardiac biomarkers testing market, by location of testing

7.3.3.Europe market size and forecast, by Biomarkers Type
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by location of testing

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.China

7.4.2.1.1.China Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.1.2.China Cardiac biomarkers testing market, by application
7.4.2.1.3.China Cardiac biomarkers testing market, by location of testing

7.4.2.2.India

7.4.2.2.1.India Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.2.2.India Cardiac biomarkers testing market, by application
7.4.2.2.3.India Cardiac biomarkers testing market, by location of testing

7.4.2.3.Australia

7.4.2.3.1.Australia Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.3.2.Australia Cardiac biomarkers testing market, by application
7.4.2.3.3.Australia Cardiac biomarkers testing market, by location of testing

7.4.2.4.Japan

7.4.2.4.1.Japan Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.4.2.Japan Cardiac biomarkers testing market, by application
7.4.2.4.3.Japan Cardiac biomarkers testing market, by location 
of testing

7.4.2.5.Rest of Asia-Pacific

7.4.2.5.1.Rest of Asia-Pacific Cardiac biomarkers testing market, by Biomarkers Type
7.4.2.5.2.Rest of Asia-Pacific Cardiac biomarkers testing market, by application
7.4.2.5.3.Rest of Asia-Pacific Cardiac biomarkers testing market, by location of testing

7.4.3.Asia-Pacific market size and forecast, by Biomarkers Type
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by location of testing

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Latin America

7.5.2.1.1.Latin America Cardiac biomarkers testing market, by Biomarkers Type

7.5.2.1.2.Latin America Cardiac biomarkers testing market, by application
7.5.2.1.3.Latin America Cardiac biomarkers testing market, by location of testing

7.5.2.2.Middle East

7.5.2.2.1.Middle East Cardiac biomarkers testing market, by Biomarkers Type
7.5.2.2.2.Middle East Cardiac biomarkers testing market, by application
7.5.2.2.3.Middle East Cardiac biomarkers testing market, by location of testing

7.5.2.3.Africa

7.5.2.3.1.Africa Cardiac biomarkers testing market, by Biomarkers Type
7.5.2.3.2.Africa Cardiac biomarker testing market, by application
7.5.2.3.3.Africa Cardiac biomarkers testing market, by location of testing

7.5.3.LAMEA market size and forecast, by Biomarkers Type
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by location of testing

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.BECTON, DICKINSON AND COMPANY

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio

8.2.5.Business performance

8.3.BIOMERIEUX, INC.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.BIO-RAD LABORATORIES, INC.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.DANAHER CORPORATION

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.F. HOFFMANN-LA ROCHE LTD.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.PERKINELMER INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.SIEMENS AG

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.THERMO FISHER SCIENTIFIC, INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.TOSOH CORPORATION

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.CONVENTIONAL DIAGNOSTICS VERSUS DIAGNOSTIC BIOMARKER TECHNIQUES
TABLE 02.GLOBAL CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKES TYPE, 2020-2030 ($MILLION)
TABLE 03.CARDIAC BIOMARKERS TESTING MARKET FOR CREATINE KINASE(CK-MB), BY REGION, 
2020-2030 ($MILLION)
TABLE 04.CARDIAC BIOMARKERS TESTING MARKET FOR TROPONINS, BY REGION, 2020-2030 ($MILLION)
TABLE 05.CARDIAC BIOMARKERS TESTING MARKET FOR MYOGLOBIN, BY REGION, 2020-2030 ($MILLION)
TABLE 06.CARDIAC BIOMARKERS TESTING MARKET FOR NATRIURETIC PEPTIDES (BNP AND NT-PROBNP), 
BY REGION, 2020-2030 ($MILLION)
TABLE 07.CARDIAC BIOMARKERS TESTING MARKET FOR ISCHEMIA MODIFIED ALBUMIN (IMA), BY REGION, 
2020-2030 ($MILLION)
TABLE 08.CARDIAC BIOMARKERS TESTING MARKET FOR OTHERS BIOMARKERS TYPE, BY REGION, 
2020-2030 ($MILLION)
TABLE 09.CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 10.CARDIAC BIOMARKERS TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 
2020-2030 ($MILLION)
TABLE 11.CARDIAC BIOMARKERS TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 
2020-2030 ($MILLION)
TABLE 12.CARDIAC BIOMARKERS TESTING MARKET FOR ACUTE CORONARY SYNDROME (ACS), BY REGION, 
2020-2030 ($MILLION)
TABLE 13.CARDIAC BIOMARKERS TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 
2020-2030 ($MILLION)
TABLE 14.CARDIAC BIOMARKERS TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 
2020-2030 ($MILLION)
TABLE 15.CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 16.CARDIAC BIOMARKERS TESTING MARKET FOR POINT OF CARE TESTING (POCT), BY REGION, 
2020-2030 ($MILLION)
TABLE 17.CARDIAC BIOMARKERS TESTING MARKET FOR LABORARTORY TESTING, BY REGION, 
2020-2030 ($MILLION)
TABLE 18.CARDIAC BIOMARKERS TESTING MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 19.NORTH AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 20.U.S. CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 21.U.S. CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 22.U.S. CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 23.CANADA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKES TYPE, 2020–2030 ($MILLION)
TABLE 24.CANADA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 25.CANADA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 26.MEXICO CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 27.MEXICO CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 28.MEXICO CARDIAC BIOMARKERS TESTING MARKET, BYLOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 29.NORTH AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 
2020–2030 ($MILLION)
TABLE 30.NORTH AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 31.NORTH AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 
2020–2030 ($MILLION)
TABLE 32.EUROPE CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 33.UK CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKET TYPE, 2020–2030 ($MILLION)
TABLE 34.UK CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 35.UK CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 36.FRANCE CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 37.FRANCE CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 38.FRANCE CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 39.GERMANY CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 40.GERMANY CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 41.GERMANY CARDIAC BIOMARKERS TESTING MARKET, BYLOCATION OF TESTING, 
2020–2030 ($MILLION)
TABLE 42.REST OF EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 
2020–2030 ($MILLION)
TABLE 43.REST OF EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 44.REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BYLOCATION OF TESTING, 
2020–2030 ($MILLION)
TABLE 45.EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKET TYPE, 2020–2030 ($MILLION)
TABLE 46.EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 47.EUROPE CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 48.ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 49.CHINA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 50.CHINA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 51.CHINA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 52.INDIA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 53.INDIA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 54.INDIA CARDIAC BIOMARKERS TESTING MARKET, BYLOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 55.AUSTRALIA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 56.AUSTRALIA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 57.AUSTRALIA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 
2020–2030 ($MILLION)
TABLE 58.JAPAN CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 59.JAPAN CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 60.JAPAN CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 61.REST OF ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE,
 2020–2030 ($MILLION)
TABLE 62.REST OF ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION,
 2020–2030 ($MILLION)
TABLE 63.REST OF ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 
2020–2030 ($MILLION)
TABLE 64.ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 
2020–2030 ($MILLION)
TABLE 65.ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 66.ASIA-PACIFIC CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 
2020–2030 ($MILLION)
TABLE 67.LAMEA CARDIAC BIOMARKERS TESTING MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 68.LATIN AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKETS TYPE, 
2020–2030 ($MILLION)
TABLE 69.LATIN AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 70.LATIN AMERICA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 
2020–2030 ($MILLION)
TABLE 71.MIDDLE EAST CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 
2020–2030 ($MILLION)
TABLE 72.MIDDLE EAST CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 73.MIDDLE EAST CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 
2020–2030 ($MILLION)
TABLE 74.AFRICA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 75.AFRICA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 76.AFRICA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 77.LAMEA CARDIAC BIOMARKERS TESTING MARKET, BY BIOMARKERS TYPE, 2020–2030 ($MILLION)
TABLE 78.LAMEA CARDIAC BIOMARKERS TESTING MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 79.LAMEA CARDIAC BIOMARKERS TESTING MARKET, BY LOCATION OF TESTING, 2020–2030 ($MILLION)
TABLE 80.ABBOTT: COMPANY SNAPSHOT
TABLE 81.ABBOTT: OPERATING SEGMENTS
TABLE 82.ABBOTT: PRODUCT PORTFOLIO
TABLE 83.BD: COMPANY SNAPSHOT
TABLE 84.BD: OPERATING SEGMENTS
TABLE 85.BD: PRODUCT PORTFOLIO
TABLE 86.BIOMÉRIEUX, INC.: COMPANY SNAPSHOT
TABLE 87.BIOMÉRIEUX, INC.: OPERATING SEGMENTS
TABLE 88.BIOMÉRIEUX: PRODUCT PORTFOLIO
TABLE 89.BIO-RAD: COMPANY SNAPSHOT
TABLE 90.BIO-RAD: OPERATING SEGMENTS
TABLE 91.BIO RAD: PRODUCT PORTFOLIO
TABLE 92.DANAHER: COMPANY SNAPSHOT
TABLE 93.DANAHER: OPERATING SEGMENTS
TABLE 94.DANAHER: PRODUCT PORTFOLIO
TABLE 95.ROCHE: COMPANY SNAPSHOT
TABLE 96.ROCHE: OPERATING SEGMENTS
TABLE 97.ROCHE: PRODUCT PORTFOLIO
TABLE 98.PERKINELMER: COMPANY SNAPSHOT
TABLE 99.PERKINELMER: OPERATING SEGMENTS
TABLE 100.PERKINELMER PRODUCT PORTFOLIO
TABLE 101.SIEMENS: COMPANY SNAPSHOT
TABLE 102.SIEMENS: PRODUCT SEGMENTS
TABLE 103.SIEMENS: PRODUCT PORTFOLIO
TABLE 104.THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 105.THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 106.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 107.TOSOH: COMPANY SNAPSHOT
TABLE 108.TOSOH: OPERATING SEGMENTS
TABLE 109.TOSOH: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.CARDIAC BIOMARKER TESTING MARKET SEGMENTATION
FIGURE 02.HIGH BARGAINING POWER OF BUYERS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE THREAT OF SUBSTITUTION
FIGURE 05.MODERATE THREAT OF NEW ENTRANTS
FIGURE 06.MODERATE COMPETITVE RIVARLY
FIGURE 07.TOP INVESTMENT POCKETS, 2020
FIGURE 08.TOP PLAYER POSITIONING, 2020
FIGURE 09.VALUE CHAIN ANALYSIS OF GLOBAL CARDIAC BIOMARKERS TESTING
FIGURE 10.IMPACT ANALYSIS
FIGURE 11.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR CREATINE KINASE
(CK-MB), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR TROPONINS, 
BY COUNTRY,  2020 & 2030 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR MYOGLOBIN, 
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR NATRIURETIC PEPTIDES 
(BNP AND NT-PROBNP), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ISCHEMIA MODIFIED
 ALBUMIN (IMA), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR OTHER BIOMARKERS 
TYPE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR MYOCARDIAL INFARCTION, 
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR CONGESTIVE HEART 
FAILURE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR ACUTE CORONARY 
SYNDROME (ACS), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR ATHEROSCLEROSIS, 
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR OTHER APPLICATIONS, 
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FORPOINT OF CARE OF 
TESTING (POCT), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF CARDIAC BIOMARKERS TESTING MARKET FOR LABORATORY TESTING, 
BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27.BD: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.BD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.BIOMÉRIEUX, INC.: REVENUE, 2018–2020 ($MILLION)
FIGURE 31.BIOMÉRIEUX: REVENUE SHARE BYSEGMENT, 2020 (%)
FIGURE 32.BIOMÉRIEUX: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33.BIO-RAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.BIO-RAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35.BIO-RAD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 36.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 37.DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 38.DANAHER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 40.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.PERKINELMER: NET SALES, 2018–2020 ($MILLION)
FIGURE 43.PERKINELMER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.PERKINELMER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45.SIEMENS: NET SALES, 2018–2020 ($MILLION)
FIGURE 46.SIEMENS: REVENUE SHARE BY PRODUCT SEGMENT, 2020 (%)
FIGURE 47.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 48.THERMO FISHER SCIENTIFIC: REVENUE, 2018–2020 ($MILLION)
FIGURE 49.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 51.TOSOH: NET SALES, 2018–2020 ($MILLION)
FIGURE 52.TOSOH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 53.TOSOH: REVENUE SHARE BY REGION, 2020 (%)

 
 

In accordance to several interviews conducted, the cardiac biomarkers testing market is expected to witness a steady growth in the future. Owing to development of novel and advanced cardiac biomarkers such as, troponin and myoglobin that would help in early detection of cardiac disorders is a major factor that boosts the market growth for cardiac biomarkers. This has increased the adoption of cardiac biomarkers across the world. Decrease in the cost of medical devices and increase in awareness for early diagnosis & prognosis of cardiac diseases have offered lucrative opportunities for the growth of the cardiac biomarkers market. Moreover, cardiac biomarkers find their application in list of chronic to mid cardiovascular conditions, which fuel their adoption across the globe, thereby propelling the market growth. The adoption of cardiac biomarkers has increased considerably, owing to their easy operational features and increase in awareness for early disease diagnosis is expected to boost the market growth in the near future.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Cardiac Biomarkers Testing Market was $9,766.93 million in 2020

A. The forecast period in the report is from 2021 to 2030

A. The CAGR of Cardiac Biomarkers Testing Market during the forecast period is 10.9%.

A. The base year for the report is 2020

A. Yes, Cardiac Biomarkers Testing Market companies are profiled in the report

A. The top companies that hold the market share in Cardiac Biomarkers Testing Market are are Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Inc., Bio-Rad Laboratories, Inc., and Danaher Corporation.

A. yes, there is value chain analysis provided in the Cardiac Biomarkers Testing Market report

A. The key trends in the Cardiac Biomarkers Testing Market are due to rise of prevalence of cardiac diseases that widely remain undiagnosed and rise in geriatric population.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Cardiac Biomarkers Testing Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers